Key Takeaways J&J advanced its pipeline in 2025 with key approvals across oncology and immunologyJNJ secured approvals for Inlexzoh, Imaavy and Icotyde, expanding treatment options and pipeline depthJNJ's new cancer drugs generated $3B in 2025, with more growth expected from launches in 2026Johnson & Johnson (JNJ) has a strong R&D pipeline, with primary focus areas being immunology, oncology and neuroscience. J&J rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones ...

Key Takeaways JNJ stock stayed above 50- and 200-day SMAs for 8 months, signaling sustained bullish momentum.J&'s growth is driven by Innovative Medicine strength, new drugs, and R&D and M&A spend.JNJ faces Stelara patent loss, China headwinds, and 74,000 talc lawsuits, impacting future outlook.Johnson & Johnson’s (JNJ) stock has remained firmly above its 50-day and 200-day simple moving averages (SMAs) for more than eight months, dating back to mid-July 2025, reflecting sustained investor confidence. Notab ...